Coherus BioSciences Files Definitive Proxy Statement

Ticker: CHRS · Form: DEF 14A · Filed: Apr 15, 2024 · CIK: 1512762

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Coherus BioSciences, Executive Compensation, Shareholder Meeting

TL;DR

<b>Coherus BioSciences filed its Definitive Proxy Statement on April 15, 2024, detailing executive compensation and corporate governance matters.</b>

AI Summary

Coherus BioSciences, Inc. (CHRS) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 15, 2024. The filing covers the period ending May 29, 2024. The company's fiscal year ends on December 31. Coherus BioSciences, Inc. was formerly known as BioGenerics, Inc. until February 10, 2011. The filing includes detailed information on equity awards and compensation for the applicable years.

Why It Matters

For investors and stakeholders tracking Coherus BioSciences, Inc., this filing contains several important signals. This DEF 14A filing is crucial for shareholders as it outlines proposals to be voted on at the upcoming annual meeting, including the election of directors and executive compensation plans. Understanding the executive compensation details and equity awards can provide insights into management's incentives and the company's financial health and future outlook.

Risk Assessment

Risk Level: — Coherus BioSciences, Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing information to shareholders rather than announcing new financial results or strategic shifts, thus posing minimal immediate risk.

Analyst Insight

Shareholders should review the proxy statement to make informed voting decisions on director nominees and executive compensation packages.

Key Numbers

Key Players & Entities

FAQ

When did Coherus BioSciences, Inc. file this DEF 14A?

Coherus BioSciences, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 15, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Coherus BioSciences, Inc. (CHRS).

Where can I read the original DEF 14A filing from Coherus BioSciences, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Coherus BioSciences, Inc..

What are the key takeaways from Coherus BioSciences, Inc.'s DEF 14A?

Coherus BioSciences, Inc. filed this DEF 14A on April 15, 2024. Key takeaways: Coherus BioSciences, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 15, 2024.. The filing covers the period ending May 29, 2024.. The company's fiscal year ends on December 31..

Is Coherus BioSciences, Inc. a risky investment based on this filing?

Based on this DEF 14A, Coherus BioSciences, Inc. presents a moderate-risk profile. The filing is a routine DEF 14A, providing information to shareholders rather than announcing new financial results or strategic shifts, thus posing minimal immediate risk.

What should investors do after reading Coherus BioSciences, Inc.'s DEF 14A?

Shareholders should review the proxy statement to make informed voting decisions on director nominees and executive compensation packages. The overall sentiment from this filing is neutral.

How does Coherus BioSciences, Inc. compare to its industry peers?

Coherus BioSciences operates in the biotechnology sector, focusing on the development and commercialization of biosimilars and innovative therapeutics.

Are there regulatory concerns for Coherus BioSciences, Inc.?

As a publicly traded company, Coherus BioSciences is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

Industry Context

Coherus BioSciences operates in the biotechnology sector, focusing on the development and commercialization of biosimilars and innovative therapeutics.

Regulatory Implications

As a publicly traded company, Coherus BioSciences is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.

What Investors Should Do

  1. Review the detailed executive compensation tables for named executive officers.
  2. Analyze proposals related to director elections and corporate governance.
  3. Understand any shareholder proposals and the board's recommendation.

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement (This form is filed by companies to solicit proxies from shareholders for annual or special meetings.)

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for shareholder meetings and does not represent a change from previous filings of this type.

Filing Stats: 4,915 words · 20 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-15 17:09:13

Filing Documents

EXECUTIVE COMPENSATION TABLES

EXECUTIVE COMPENSATION TABLES 51 EQUITY COMPENSATION PLAN INFORMATION 58

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 59 SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE 62 PAY VERSUS PERFORMANCE 63 ADDITIONAL INFORMATION 67 APPENDIX A 69 3 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This proxy statement contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements that are not statements of historical facts contained in this proxy statement may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by words such as "aim," "anticipate," "assume," "attempt," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "seek," "should," "strive," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about our expected overhang rate at the end of 2024. We have based these forward-looking statements on our current expectations about future events. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Our actual results may differ materially from those suggested by these forward-looking statements for various reasons, including those identified in Part I, Item 1A of our Annual Report on Form 10 K for the fiscal year ended December 31, 2023 filed on March 15, 2024 under the heading "Risk Factors." Given these risks and uncertainties, you are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements included in this proxy statement are made only as of the date hereof. Except as required under federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not undertake, and specifically decline, any ob

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing